Opportunity Information: Apply for RFA CK 14 005
Apply for RFA CK 14 005
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "A Creutzfeldt Jakob Disease (CJD) Lookback Study Assessing the Risk of Blood Borne Transmission of Classic Forms of Creutzfeldt Jakob Disease" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.084 Prevention of Disease, Disability, and Death by Infectious Diseases.
- This funding opportunity was created on Feb 26, 2014 and posted on Jan 17, 2014.
- Applicants must submit their applications by Mar 20, 2014 Application Due Date March 20, 2014, by 500 PM U.S. Eastern Time. Letter of Intent Not Applicable. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $380,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $76,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Eligible Organizations The American Red Cross
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity, RFA CK 14 005, is a Centers for Disease Control and Prevention (CDC) cooperative agreement focused on continuing a long-running public health investigation known as the Creutzfeldt Jakob Disease (CJD) Lookback Study. The central aim is to have the American Red Cross (ARC) maintain and carry forward an active, nationwide study that originally began in 1995. The study tracks and evaluates recipients of blood and blood products from donors who were later identified as having classic forms of CJD, with the goal of assessing whether, and to what extent, CJD can be transmitted through blood transfusion in the United States. In practical terms, this kind of "lookback" study is designed to reconstruct and follow transfusion chains after a donor is found to have a condition of concern, then monitor outcomes among recipients over time to detect potential transmission events and better quantify risk.
The award mechanism is a cooperative agreement, which generally means CDC expects to be substantively involved with the recipient during the project period rather than simply providing a grant with minimal ongoing engagement. The activity category is health, and it falls under CFDA 93.084, which is aimed at prevention of disease, disability, and death by infectious diseases. The announcement anticipated a single award (ExpectedAwards: 1), reflecting that this work is intended to be conducted by a specific entity with the necessary national blood collection and tracing infrastructure. Consistent with that, eligibility is restricted to the American Red Cross, as explicitly stated in the eligibility information. There is no cost sharing or matching requirement.
In terms of funding level, the announcement listed an estimated total funding amount of $380,000, with an award ceiling of $76,000 and an award floor of $70,000. These figures suggest a relatively tightly bounded annual budget range with an overall multi-year estimate (the total estimate is larger than the single-year ceiling/floor amounts), which is typical when an agency forecasts funding across an anticipated project period while also stating expected per-budget-period levels. The opportunity was posted on January 17, 2014, created on February 26, 2014, and the original application due date was February 25, 2014 at 5:00 PM U.S. Eastern Time. The due date was later extended to March 20, 2014 at 5:00 PM U.S. Eastern Time, and the archive date was April 19, 2014. A letter of intent was not applicable.
Overall, the opportunity is best understood as targeted support to sustain an established national surveillance and epidemiologic follow-up effort managed by the ARC, with CDC backing, to clarify the real-world risk of transfusion-associated transmission of classic CJD. Because CJD is a rare but severe neurodegenerative disease with long incubation periods and major implications for blood safety policy, long-term follow-up and comprehensive tracing are essential to detect any signal of transmission, rule out transmission with greater confidence, and inform ongoing donor screening, deferral policies, and blood safety practices in the United States.
For access issues related to the full announcement, the listed contact is the CDC Procurement and Grants Office (PGO), Technical Information Management Section (TIMS), at 770-488-2700.
Frequently Asked Questions (FAQs) - CDC Cooperative Agreement RFA CK 14 005 (CJD Lookback Study)
What is RFA CK 14 005?
RFA CK 14 005 is a Centers for Disease Control and Prevention (CDC) funding opportunity issued as a cooperative agreement to continue the Creutzfeldt Jakob Disease (CJD) Lookback Study, a long-running public health investigation that began in 1995.
What is the purpose of this funding opportunity?
The central aim is to support the American Red Cross (ARC) in maintaining and continuing an active, nationwide study that tracks and evaluates recipients of blood and blood products from donors who were later identified as having classic forms of CJD. The overall goal is to assess whether, and to what extent, classic CJD can be transmitted through blood transfusion in the United States.
What is the CJD Lookback Study?
The CJD Lookback Study is an ongoing “lookback” investigation designed to reconstruct and follow transfusion chains after a blood donor is later found to have a condition of concern (here, classic CJD). The study then monitors outcomes among recipients over time to detect possible transmission events and better quantify transfusion-related risk.
Why is a lookback study used for this topic?
This type of study is used to trace prior blood and blood product recipients when a donor is later identified as having classic CJD, and to support long-term monitoring of recipients. This approach is especially relevant because CJD is rare, severe, and associated with long incubation periods, making extended follow-up and comprehensive tracing important for detecting or ruling out transfusion-associated transmission.
Who is eligible to apply?
Eligibility is restricted to the American Red Cross (ARC), as explicitly stated in the eligibility information for the opportunity.
How many awards were expected under this announcement?
The announcement anticipated a single award (ExpectedAwards: 1).
What type of funding mechanism is used?
The award mechanism is a cooperative agreement. This generally means CDC expects to be substantively involved with the recipient during the project period, rather than providing a grant with minimal ongoing engagement.
Which federal program or CFDA number is associated with this opportunity?
This opportunity falls under CFDA 93.084, which is aimed at prevention of disease, disability, and death by infectious diseases.
What is the activity category for this opportunity?
The activity category is health.
What is the estimated total funding amount?
The estimated total funding amount listed in the announcement is $380,000.
What are the award ceiling and award floor amounts?
The award ceiling is $76,000 and the award floor is $70,000.
Is there a cost sharing or matching requirement?
No. The announcement states there is no cost sharing or matching requirement.
When was the opportunity posted and created?
The opportunity was posted on January 17, 2014, and created on February 26, 2014.
What was the original application due date and time?
The original application due date was February 25, 2014 at 5:00 PM U.S. Eastern Time.
Was the application due date extended?
Yes. The due date was later extended to March 20, 2014 at 5:00 PM U.S. Eastern Time.
What is the archive date for this opportunity?
The archive date listed for the opportunity is April 19, 2014.
Was a letter of intent required or applicable?
A letter of intent was not applicable.
What outcomes or questions is the study intended to address?
The study is intended to clarify the real-world risk of transfusion-associated transmission of classic CJD in the United States by tracking recipients linked to donors later identified as having classic CJD and monitoring outcomes over time.
Why does the opportunity focus on long-term follow-up?
The opportunity emphasizes long-term follow-up because CJD has long incubation periods and is rare but severe, so extended monitoring and comprehensive tracing are important to detect any potential signal of transmission, rule out transmission with greater confidence, and inform blood safety practices.
What organization is expected to carry out the nationwide tracing and follow-up work?
The American Red Cross (ARC) is expected to maintain and carry forward the nationwide study.
What should someone do if they have trouble accessing the full announcement?
For access issues related to the full announcement, the listed contact is the CDC Procurement and Grants Office (PGO), Technical Information Management Section (TIMS), at 770-488-2700.
Browse more opportunities from the same category: Health
Next opportunity: NIH Directors Biomedical Research Workforce Innovation Award Broadening Experiences in Scientific Training (BEST) (DP7)
Previous opportunity: U.S. Consulate Hyderabad Workshop on Media Coverage of Foreign Affairs
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CK 14 005
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CK 14 005) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIH Directors Biomedical Research Workforce Innovation Award Broadening Experiences in Scientific Training (BEST) (DP7) Apply for RFA RM 13 019 Funding Number: RFA RM 13 019 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Community Health Projects Related to Contamination at Brownfield/Land Reuse Sites (ATSDR CHPs) Apply for CDC RFA TS14 1404 Funding Number: CDC RFA TS14 1404 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $150,000 |
| Secretarys Minority AIDS Initiative Funding to Increase HIV Prevention and Care Service Delivery among Health Centers Serving High HIV Prevalence Jurisdictions Apply for CDC RFA PS14 1410 Funding Number: CDC RFA PS14 1410 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $850,000 |
| Kyrgyzstan TB Program Apply for RFA 176 14 000005 Funding Number: RFA 176 14 000005 Agency: Kazakhstan USAID Almaty Category: Health Funding Amount: $12,800,000 |
| Well Integrated Screening and Evaluation for Women Across the Nation (WISEWOMAN) Program Apply for CDC RFA DP13 130202CONT14 Funding Number: CDC RFA DP13 130202CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Notification of Request for comments on potential RFA for implementation of the Integrated Family Health Program (IFHP) II in Ethiopia Apply for RFA 663 14 000002 Funding Number: RFA 663 14 000002 Agency: Ethiopia USAID Addis Ababa Category: Health Funding Amount: $75,000,000 |
| Research Centers for Pharmacogenomics in Precision Medicine (P50) Apply for PAR 14 075 Funding Number: PAR 14 075 Agency: National Institutes of Health Category: Health Funding Amount: $1,750,000 |
| Beyond HAART Innovative Approaches to Cure HIV 1 (U19) Apply for RFA AI 14 004 Funding Number: RFA AI 14 004 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Mutant Mouse Resource and Research Centers (U42) Apply for RFA OD 14 003 Funding Number: RFA OD 14 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Drug Free Communities Program Apply for SP 14 002 Funding Number: SP 14 002 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $125,000 |
| Healthy Communities, Tobacco Control, Diabetes Prevention and Control, and Behavioral Risk Factor Surveillance System Apply for CDC RFA DP14 1415 Funding Number: CDC RFA DP14 1415 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Postbaccalaureate Research Education Program (PREP) (R25) Apply for PAR 14 076 Funding Number: PAR 14 076 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Novel, Alternative Model Systems for Enteric Diseases (U19) Apply for RFA AI 14 011 Funding Number: RFA AI 14 011 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Part C Capacity Development Program Apply for HRSA 14 061 Funding Number: HRSA 14 061 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Services Grant Program for Residential Treatment for Pregnant and Postpartum Women (Short Title PPW) Apply for TI 14 005 Funding Number: TI 14 005 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $524,000 |
| International Research in Infectious Diseases, including AIDS (R01) Apply for PAR 14 080 Funding Number: PAR 14 080 Agency: National Institutes of Health Category: Health Funding Amount: $625,000 |
| Network and Infrastructure Support for Development of Interdisciplinary Aging Research (R24) Apply for PAR 14 081 Funding Number: PAR 14 081 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Ryan White HIV/AIDS Program National HIV Training and Technical Assistance Cooperative Agreements Apply for HRSA 14 035 Funding Number: HRSA 14 035 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC) Apply for CDC RFA PS14 1407 Funding Number: CDC RFA PS14 1407 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Affordable Care Act Mental Health Service Expansion Behavioral Health Integration (BHI) Apply for HRSA 14 110 Funding Number: HRSA 14 110 Agency: Health Resources and Services Administration Category: Health Funding Amount: $250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CK 14 005", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.